Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Exosome Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD9 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD9 LEL-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed. |
View CD9 Products |
| Gene Delivery | CD9 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for conformational tetraspanin assays. |
View CD9 Products |
| Benchmark Ab | Anti-CD9 Recombinant Antibody Recombinant positive control for binding and flow cytometry assays. |
View CD9 Products |
| Validator | CD9 siRNA Set For knockdown verification in functional and phenotypic assays. |
View CD9 Products |
| Related Target A | CD63 Co-expressed tetraspanin; critical for multiplex exosome profiling and specificity screening. |
View CD63 Products |
| Related Target B | CD81 Synergistic tetraspanin marker; key target for cross-reactivity and selectivity panels. |
View CD81 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of Tetraspanin Loops | HEK293 mammalian expression system preserves native post-translational modifications and disulfide bonds of the CD9 Large Extracellular Loop (LEL). |
| Cell-Based Screening of Multi-Pass Membrane Proteins | High-titer Lentiviral Particles enable stable full-length CD9 expression, bypassing the need for complex VLP reconstitutions. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies available as in vitro assay controls. |
| False Positives | Highly specific CD9 siRNA knockdown pools included to confirm target-specific binding. |
Live CD9 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD9 therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies to CD9-targeted ADCs and exosome-mediated delivery systems. As first-generation therapies reach the clinic, the next wave of R&andD is targeting tumor-specific glycoforms and conformational epitopes of CD9 to minimize systemic toxicity while maximizing therapeutic index in solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugates (ADCs) | Biotech Innovators, Academic Medical Centers | Solid Tumors (Pancreatic, Lung, Breast Cancer) | Internalization Assay (Need high-purity CD9 LEL-Fc to validate receptor-mediated endocytosis) |
| Exosome-Targeted Therapeutics | Exosome Therapeutics Developers | Metastatic Cancers, Inflammatory Diseases | Heterodimer Validation (Need high-purity CD63/CD81 proteins to verify exosome capture efficiency) |
| Monoclonal Antibodies (mAbs) | Oncology-focused Biopharma | Hematological Malignancies, Solid Tumors | Selectivity Assay (Need Lentivirus for stable cell lines to perform high-throughput flow cytometry screening) |